tbuckley/cabot-search huggingface dataset:
Abstract 11589: Accelerated Atherosclerosis Development in C57BL6 Mice by Overexpressing Adeno-associated Virus-mediated Gain-of-function Mutant of Proprotein Convertase Subtilisin/kexin Type 9 Gene and Partial Carotid Ligation
Authors: Sandeep Kumar, Dong Won Kang, Amir Rezvan, Hanjoong Jo
Journal: Circulation (2017)

Introduction: Studying the role of a particular gene in atherosclerosis typically requires a time-consuming and often difficult process of generating double-knockouts or transgenics on ApoE-/- or L...
Delayed onset immune related adverse effects (IRAEs) of pembrolizumab in non-small cell lung cancer
Authors: H. Yan, Y. Jiang, M.K. Luong, N. Naban, C. Kane, J. Conibear, D. Papadatos-Pastos, T. Ahmad, D. Chao, U.S. Asghar, G. Anand
Journal: Annals of Oncology (2019)
Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
Authors: E. Capelletto, A. Morabito, F. Grossi, F Di Costanzo, G. Osman, R. Chiari, P. Bordi, V. Scotti, G. Romano, A. Delmonte, D. Galetta, L. Ciuffreda, A. Manzo, C. Genova, F. Mazzoni, A.M. Morelli, R. Critelli, I. Stura, G. Migliaretti, S. Novello
Journal: Annals of Oncology (2019)
Concerns Regarding a Meta-analysis Comparing Psychotherapy With Medications for Posttraumatic Stress Disorder
Authors: Wei Zheng, Han Qi, Yu-Tao Xiang
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): An analysis of the TAGS study
Authors: M. Alsina, J. Tabernero, H.-T. Arkenau, M. Squadroni, T. Doi, C. Faustino, M. Ghidini, W. Mansoor, K. Shitara, E. Van Cutsem, N. Causse-Amellal, C. Leger, D. Skanji, D. Ilson
Journal: Annals of Oncology (2019)
Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2.
Authors: Kathleen I. Pritchard, Howard A. Burris, Hope S. Rugo, Michael Gnant, José Baselga, Martine J. Piccart-Gebhart, Shinzaburo Noguchi, Shaker R. Dakhil, Vichien Srimuninnimit, Puttisak Puttawibul, Karen Osborne, Pabak Mukhopadhyay, Tanya Taran, Tarek Sahmoud, Mario Campone, Gabriel N. Hortobagyi
Journal: Journal of Clinical Oncology (2012)

551 Background: Postmenopausal women with estrogen-receptor–positive (ER + ) BC who relapse/progress on a nonsteroidal aromatase inhibitor (NSAI) are usually treated with the steroidal AI exemestane (EXE); but there is no currently approved treatment for this indication. The BOLERO-2 trial showed that adding everolimus (EVE), an oral inhibitor of mammalian target of rapamycin (mTOR), to EXE significantly improved clinical benefit beyond that of EXE alone (Hortobagyi et al, SABCS 2011, Abstract S3-7). As many women with advanced BC are elderly, the tolerability profile of EVE + EXE in this population is of interest. Methods: BOLERO-2 is a phase III, randomized, trial comparing EVE (10 mg once daily) vs placebo (PBO), both plus EXE (25 mg once daily) in postmenopausal women with advanced ER + BC progressing or recurring after NSAIs. Safety data with a focus on elderly patients are reported at 12.5 mo median follow-up. Results: Baseline disease characteristics, age, and prior cancer therapy were well balanced between treatment arms (N = 724). At 12.5 months’ median follow-up, the addition of EVE to EXE significantly improved progression-free survival in patients &lt;65 (HR = 0.37; P &lt; .05) or ≥65 years of age (HR = 0.56; P &lt; .05). Adverse events (AEs) of special interest (all grades) occurring more frequently with EVE vs PBO (overall study population) included stomatitis (66.6% vs 11.3%), infections (50.4% vs 25.2%), rash (44.0% vs 8.4%), pneumonitis (18.7% vs 0.4%), and hyperglycemia (15.4% vs 2.5%). Elderly EVE-treated patients (≥65 years) had similar or marginally lower incidence of stomatitis (52.1%), rash (32.3%), pneumonitis (14.6%), and hyperglycemia (12.5%) compared with the overall population. Grade 3/4 AEs in patients ≥70 years of age (n = 161) reported only among patients receiving EVE (n = 118) included fatigue (10.2%), anemia (10.2%), hyperglycemia (8.5%), stomatitis (7.6%), dyspnea (6.8%), pneumonitis (5.1%), neutropenia (3.4%), and hypertension (3.4%). Conclusions: Adding EVE to EXE was well tolerated in the overall population and in elderly patients with advanced BC; grade 3/4 AEs were uncommon and manageable. Overall, AEs were consistent with the known safety profile of EVE.
Criminalization of Opioid Civil Commitment
Authors: Paul P. Christopher, Paul S. Appelbaum, Michael D. Stein
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Outcome of non-metastatic male breast cancer: 222 patients
Authors: U.Y. Arslan, F. Aslan, M. Ayhan, N. Akdeniz, G. Tahtacı, H Yeşil Çınkır, M. inanc, G.I. Imamoglu, N. Alkış, N. Turan, M.A. Kaplan, N.Y. ozdemir, O B Cakmak Oksuzoglu
Journal: Annals of Oncology (2019)
Two years of BRCA1 and BRCA2 somatic external quality assessment with Gen&amp;Tiss scheme in France
Authors: K. Dufraing, C. Garrec, C. Egele, C. Keppens, J. Chiesa, A. Lamy, L. Lacroix, A. Harlé, R. Pascal, K. Van Casteren, D. Fetique, E. Dequeker, J.-P. Bellocq, E. Rouleau
Journal: Annals of Oncology (2019)
Biliopancreatic Diversion Induces Greater Metabolic Improvement Than Roux-en-Y Gastric Bypass
Authors: Lydia-Ann Harris, Brandon D. Kayser, Consuelo Cefalo, Luca Marini, Jeramie D. Watrous, Jeffrey Ding, Mohit Jain, Jeffrey G. McDonald, Bonne M. Thompson, Elisa Fabbrini, J. Christopher Eagon, Bruce W. Patterson, Bettina Mittendorfer, Geltrude Mingrone, Samuel Klein
Journal: Cell Metabolism (2019)
The impact of the ABC transporters P-gp and BCRP on the oral bioavailability and brain penetration of erlotinib using drug transporter knockout mouse models.
Authors: Olaf van Tellingen, Serena Marchetti, Nienke de Vries, Jin Zhao, Tessa Buckle, Jos Beijnen, Jan Schellens
Journal: Cancer Research (2007)

LB-373  The ABC transporters P-glycoprotein (Pgp, MDR1, ABCB1), breast cancer resistance protein (BCRP, ABCG2) and multidrug resistance protein 2 (MRP2, ABCC2) are involved in the disposition of xenobiotics, including many currently used anticancer drugs. Erlotinib (Tarceva®) is an orally active epidermal growth factor receptor 1 (EGFR1) inhibitor approved by the FDA for use in non small-cell lung cancer (NSCLC) but also in clinical trials for other oncology indications.  We have first established by in vitro transwell assays that erlotinib is a substrate of Pgp and BCRP but not of MRP2. In vitro experiments using MDCK-parent and MDCK-Bcrp1 cells showed clear vectorial transport of erlotinib in the latter that was abrogated by the Pgp/BCRP inhibitor elacridar and similar results were obtained with LLC-PK1 versus LLC-Mdr1a and LLC-MDR1 cell lines.  >In further experiments using wild-type (WT), Mdr1a/b, Bcrp1 and Mdr1a/b-Bcrp1 knockout mice, we have studied the impact of these transporters on the oral bioavailability and blood-brain barrier penetration of erlotinib. To establish the oral bioavailability, erlotinib was injected i.p. or given orally by gavage at a dose level of 5 mg/kg. Serial blood samples were taken from the tail vein between 5 min and 10 h post drug administration. Plasma levels were determined by a validated HPLC method. The plasma clearance of erlotinib was 11.0 ± 1.8 and 11.1 ± 2.9 mg/l*h in WT and Mdr1a/b-Bcrp1 knockout mice, respectively. The oral bioavailability of erlotinib was 47.1 ± 6.8 and 60.1 ± 6.0% in WT and Mdr1a/b-Bcrp1 knockout mice, respectively (p = NS), thus demonstrating a trend to a minor and probably not clinically relevant enhancement of the oral bioavailability when both P-gp and Bcrp are fully absent. This result suggests that an alteration in the clearance of erlotinib due to interactions on Pgp and/or BCRP is an unlikely event.  >In a subsequent set of experiments we have investigated the brain penetration of erlotinib. Animals were killed at 1, 4 and 8 h after i.p administration of 50 mg/kg erlotinib. Blood, brain and other tissues were homogenized and analyzed. The AUC of erlotinib in the brains of WT, Mdr1a/b, Bcrp1 and Mdr1a/b-Bcrp1 knockout mice were 11.0 ± 1.35, 31.1 ± 1.70**, 13.0 ± 0.70 and 49.6 ± 3.95** µg/g*h, respectively (**p
Identification of neurobehavioural symptom groups based on shared brain mechanisms
Authors: Alex Ing, Philipp G Sämann, Congying Chu, Nicole Tay, Francesca Biondo, Gabriel Robert, Tianye Jia, Thomas Wolfers, Sylvane Desrivières, Tobias Banaschewski, Arun L W Bokde, Uli Bromberg, Christian Büchel, Patricia Conrod, Tahmine Fadai, Herta Flor, Vincent Frouin, Hugh Garavan, Philip A Spechler, Penny Gowland, Yvonne Grimmer, Andreas Heinz, Bernd Ittermann, Viola Kappel, Jean-Luc Martinot, Andreas Meyer-Lindenberg, Sabina Millenet, Frauke Nees, Betteke van Noort, Dimitri Papadopoulos Orfanos, Marie-Laure Paillère Martinot, Jani Penttilä, Luise Poustka, Erin Burke Quinlan, Michael N Smolka, Argyris Stringaris, Maren Struve, Ilya M Veer, Henrik Walter, Robert Whelan, Ole A Andreassen, Ingrid Agartz, Hervé Lemaitre, Edward D Barker, John Ashburner, Elisabeth Binder, Jan Buitelaar, Andre Marquand, Trevor W Robbins, Gunter Schumann
Journal: Nature Human Behaviour (2019)
Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
Authors: L.A. Emens, F.J. Esteva, M. Beresford, C. Saura, M. De Laurentiis, S.-B. Kim, S.-A. Im, Y. Wang, A. Mani, J. Shah, H. Liu, S. de Haas, M. Patre, S. Loi
Journal: Annals of Oncology (2019)
Selective Serotonin Reuptake Inhibitor Use During Pregnancy—Associated With but Not Causative of Autism in Offspring
Authors: José M. Flores, Victor J. Avila-Quintero, Michael H. Bloch
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates
Authors: Leigh Goedeke, Liang Peng, Valle Montalvo-Romeral, Gina M. Butrico, Sylvie Dufour, Xian-Man Zhang, Rachel J. Perry, Gary W. Cline, Paul Kievit, Keefe Chng, Kitt Falk Petersen, Gerald I. Shulman
Journal: Science Translational Medicine (2019)

Nonalcoholic fatty liver disease (NAFLD) is estimated to affect up to one-third of the general population, and new therapies are urgently required. Our laboratory previously developed a controlled-release mitochondrial protonophore (CRMP) that is functionally liver-targeted and promotes oxidation of hepatic triglycerides. Although we previously demonstrated that CRMP safely reverses hypertriglyceridemia, fatty liver, hepatic inflammation, and fibrosis in diet-induced rodent models of obesity, there remains a critical need to assess its safety and efficacy in a model highly relevant to humans. Here, we evaluated the impact of longer-term CRMP treatment on hepatic mitochondrial oxidation and on the reversal of hypertriglyceridemia, NAFLD, and insulin resistance in high-fat, fructose-fed cynomolgus macaques (n = 6) and spontaneously obese dysmetabolic rhesus macaques (n = 12). Using positional isotopomer nuclear magnetic resonance tracer analysis (PINTA), we demonstrated that acute CRMP treatment (single dose, 5 mg/kg) increased rates of hepatic mitochondrial fat oxidation by 40%. Six weeks of CRMP treatment reduced hepatic triglycerides in both nonhuman primate models independently of changes in body weight, food intake, body temperature, or adverse reactions. CRMP treatment was also associated with a 20 to 30% reduction in fasting plasma triglycerides and low-density lipoprotein (LDL)-cholesterol in dysmetabolic nonhuman primates. Oral administration of CRMP reduced endogenous glucose production by 18%, attributable to a 20% reduction in hepatic acetyl-coenzyme A (CoA) content [as assessed by whole-body β-hydroxybutyrate (β-OHB) turnover] and pyruvate carboxylase flux. Collectively, these studies provide proof-of-concept data to support the development of liver-targeted mitochondrial uncouplers for the treatment of metabolic syndrome in humans.
Targeting PD-L1 After Adjuvant Radiation in Subtotally Resected Primary Pineal Melanoma: A Case Report and Literature Review
Authors: Justin Famoso, Gerald Lemole, Srinath Sundararajan, Baldassarre Stea
Journal: Journal of the National Comprehensive Cancer Network (2019)

Primary melanoma of the pineal gland is a rare disease entity with an overall poor prognosis. Limited data exist to appropriately guide treatment decisions. Historical case reports have showed some success using a combination of surgical resection, radiotherapy, and chemotherapy, but long-term survival has been exceedingly rare. This report presents a female patient with a primary pineal melanoma who underwent subtotal resection followed by adjuvant focal radiation to the residual tumor. Immunohistochemistry identified a strong positivity for PD-L1 (70%). After radiation, systemic therapy with pembrolizumab was initiated with the plan to treat until progression. She has now completed 33 cycles of pembrolizumab without interruptions, complications, or disease progression. At the time of writing, the patient has had an excellent clinical outcome, with a durable near-complete response of &gt;138 weeks. To our knowledge, this is the first patient with a pineal melanoma to be managed by targeting PD-L1. Furthermore, she has achieved the second longest overall survival and the longest progression-free survival reported in the literature.
Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma
Authors: Kenjiro Namikawa, Phyu P. Aung, Denái R. Milton, Michael T. Tetzlaff, Carlos A. Torres-Cabala, Jonathan L. Curry, Priyadharsini Nagarajan, Doina Ivan, Merrick Ross, Jeffrey E. Gershenwald, Victor G. Prieto
Journal: Clinical Cancer Research (2019)

In patients with cutaneous melanoma, metastasis in a nonsentinel lymph node (non-SLN) is a strong independent adverse prognostic factor. However, patients with a tumor-involved SLN no longer routinely undergo completion lymph node dissection (CLND). We hypothesized that SLN tumor burden may predict non-SLN tumor burden.We compared tumor burden parameters between SLN and non-SLN in patients with cutaneous melanoma who underwent SLN biopsy with a positive SLN during 2003 to 2008 at The University of Texas MD Anderson Cancer Center.We identified 336 eligible patients with a positive SLN. Of these, 308 (92%) underwent CLND, and 35 (10%) had non-SLN metastasis. The median follow-up time was 6.0 years. For patients with maximum diameter of tumor in the SLN ≤2.0 mm, >2.0-5.0 mm, and >5.0 mm, non-SLN metastasis was detected in 5 of 200 patients (3%), 10 of 63 patients (16%), and 20 of 57 patients (35%), and the mean maximum diameters of the non-SLN tumor deposits were 0.09, 1.56, and 2.71 mm, respectively (P < 0.0001). The percentage of patients with both subcapsular and intraparenchymal non-SLN tumor was higher for patients with SLN tumor in both locations than for patients with SLN tumor in only one location (P < 0.0001). Extranodal extension in a non-SLN was more common in patients with extranodal extension in an SLN (P = 0.003).In patients with cutaneous melanoma who undergo CLND, SLN tumor burden predicts non-SLN tumor burden. SLN tumor burden parameters provide accurate prognostic stratification independent of non-SLN status and should be considered for incorporation into future staging systems and integrated risk models.
Differential regulation of nuclear receptors and aminoacyl-TRNA-synthetases by endocrine disrupting chemicals
Authors: Courtney Johnson, Erica McElroy, Hari Cohly, Raphael Isokpehi, Rajendram Rajnarayanan
Journal: Cancer Research (2008)

1648  Endocrine Disrupting Chemicals (EDC) include phenolic hormone mimics diethylstilbestrol, bisphenol A, dioxins, polychlorinated biphenyls and pesticides like dichloro-diphenyl-trichloroethane, that disrupt the physiologic function of hormones involving the reproductive system. EDCs have been shown to alter nuclear receptors and other transcription factors. To establish a clear link between EDC exposure and the regulation of NR and tRNA synthetase function, we examined a battery of microarray databases for the alteration of gene expressions as a function of EDC exposure. EndNote Connect Tools combined with customized scripts were used to collect literature and microarray data. Public domain databases used were NCBI Gene Expression Ominibus datasets, PubMed, PubChem and Comparative Toxicogenomics Database (CTD). We established chemical interaction linkages between tRNA synthetase, nuclear receptors and their primary protein-protein interaction network. Overall, 503 protein-protein interactions and 4565 EDC-Protein interactions were analyzed to generate a comprehensive graphical interaction map. These maps showed that at least 7 tRNA synthetases and almost all nuclear receptors are regulated by EDCs. Endogenous estrogens, isoflavones and alkylphenols increase tyrosyl and tryptophanyl tRNA synthetase expression. However, this effect is not observed in other tRNA synthetases. Sequence analyses revealed a striking similarity in the C-terminal residues of estrogen receptor, tyr and trp-tRNA synthetases indicating the possibility of direct binding events. Our observations provide valuable insight into the hormonal control of protein expression/function and structural basis for drug discovery.  Acknowledgement: NSF C-RUI Grant #0215924 (EM & RVR) and NHLBI-Jackson Heart Study (CJ).
Kartogenin hydrolysis product 4-aminobiphenyl distributes to cartilage and mediates cartilage regeneration
Authors: Shuai Zhang, Peilin Hu, Tao Liu, Zhen Li, Yongcan Huang, Jinqi Liao, Md Rana Hamid, Liru Wen, Ting Wang, Cuiping Mo, Mauro Alini, Sibylle Grad, Tianfu Wang, Di Chen, Guangqian Zhou
Journal: Theranostics (2019)

Rationale The small molecule Kartogenin (KGN) promotes cartilage regeneration in osteoarthritis (OA) by activating stem cells differentiation, but its pharmacological mode-of-action remains unclear. KGN can be cleaved into 4-aminobiphenyl (4-ABP) and phthalic acid (PA) following enzymolysis of an amide bond. Therefore, this study investigated whether 4-ABP or PA exerted the same action as KGN. Methods KGN, 4-ABP and PA were analyzed in cartilage of mice after oral, intravenous or intra-articular administration of KGN by liquid chromatography-mass spectrometry method. Their effect on proliferation and chondrogenic differentiation of mesenchymal stem cells (MSC) was evaluated in vitro. Furthermore, their effect on cartilage preservation was tested in mice OA model induced by destabilization of medial meniscus. OA severity was quantified using OARSI histological scoring. Transcriptional analysis was used to find the possible targets of the chemicals, which were further validated. Results We demonstrated that while oral or intra-articular KGN delivery effectively ameliorated OA phenotypes in mice, only 4-ABP was detectable in cartilage. 4-ABP could induce chondrogenic differentiation and proliferation of MSC in vitro and promote cartilage repair in OA mouse models mainly by increasing the number of CD44+/CD105+ stem-cell and prevention of matrix loss. These effect of 4-ABP was stronger than that of KGN. Transcriptional profiling of 4-ABP-stimulated MSC suggested that RPS6KA2 and the PI3K-Akt pathway were 4-ABP targets; 4-ABP could activate the PI3K-Akt pathway to promote MSC proliferation and repair OA injury, which was blocked in RPS6KA2-knockdown MSC or RPS6KA2-deficient mice.Conclusion 4-ABP bio-distribution in cartilage promotes proliferation and chondrogenic differentiation of MSC, and repairs osteoarthritic lesions via PI3K-Akt pathway activation.
Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm
Authors: Lisa Pieri, Chiara Paoli, Umberto Arena, Fabio Marra, Fabio Mori, Mery Zucchini, Stefano Colagrande, Alessandro Castellani, Arianna Masciulli, Vittorio Rosti, Valerio De Stefano, Silvia Betti, Guido Finazzi, Maria Luisa Ferrari, Elisa Rumi, Marco Ruggeri, Ilaria Nichele, Paola Guglielmelli, Rajmonda Fjerza, Carmela Mannarelli, Tiziana Fanelli, Lucia Merli, Margherita Massa, Giuseppe Cimino, Alessandro Rambaldi, Giovanni Barosi, Mario Cazzola, Tiziano Barbui, Alessandro M. Vannucchi
Journal: Blood (2015)
Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer
Authors: T.Y. Semiglazova, M. Osipov, P. Krivorotko, S. Protsenko, V. Semiglazov, R. Donskih, V. Klimenko, E. Tsirlina, L. Berstein, V. Anisimov, V. Semiglazov, A. Belyaev
Journal: Annals of Oncology (2019)